SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel

SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing tarumase (provisional INN), a recombinant enzyme derived from maggots, and which aims to accelerate wound debridement and contribute to wound bed preparation & healing, today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).

SolasCure’s CLEANVLU Phase IIa clinical trial observed a strong safety profile for Aurase Wound Gel, with no evidence of systemic availability, no antibody generation to the enzyme and no effects on systemic coagulation pathways. In addition, no local tolerability issues (erythema, oedema, induration, or bleeding) and no pain from application of the gel was observed. The trial also indicated a dose-dependent effect on wound debridement with higher concentrations of enzyme resulting in more complete debridement, a faster rate of debridement, and an improved wound healing trajectory. The study was performed at centres in the US, UK, and Hungary.

SolasCure’s Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots, aims to facilitate debridement, reduce bacterial biofilm, and promote wound bed preparation and healing. Aurase Wound Gel is due to enter further Phase II trials to further evaluate its efficacy across a larger and more diverse patient group than the Phase IIa study, with the positive safety data obtained from the Phase IIa trial allowing for higher concentrations of the gel to now be explored.

Chronic wounds are a huge unmet medical need with treatment costs accounting for approximately 1-3% of total healthcare expenditure in developed countries.1 With over 40 million chronic wounds requiring debridement each year globally, the need for better debridement, wound bed preparation and healing is a growing and urgent problem, currently without safe, pain-free, and effective solutions.

Strengthening SolasCure’s leadership team as it moves towards further Phase II clinical trials, medical expert Andy Weymann has been appointed as Chairman of the Board.

Andy Weymann M.D., newly appointed Chairman of the Board, SolasCure, said: “I am delighted to join the SolasCure team, especially at such an exciting phase of growth. The positive safety and proof-of-concept data from the Phase IIa trial represents a huge milestone for the Company, accelerating its mission to provide a disruptive wound care product that could significantly improve outcomes for patients with chronic wounds globally. I look forward to working alongside the team as we now focus on developing the efficacy of Aurase Wound Gel in subsequent Phase II trials.”

Andy Weymann is an orthopaedic surgeon with 25 years’ experience in the medical device and regenerative medicine industries. Andy has held several global executive and Board roles throughout his career, including Chief Medical Officer and Senior Vice President of Scientific, Clinical and Medical Affairs at Smith+Nephew. Andy completed his Masters in Human Medicine at the University of Zurich, Switzerland, an MBA at the Simon Business School, University of Rochester, NY, and his Board Program at Harvard, Boston, MA.

Rob Kirsner, M.D., PhD, Head of Medical Advisory Board at SolasCure, Chairman and Harvey Blank Professor of Dermatology at the University of Miami, added: “SolasCure’s Aurase Wound Gel is an innovative technology, harnessing an enzyme cloned from medical maggots to accelerate wound cleaning, and therefore healing. We have a shared vision to deliver a meaningful solution for patients with chronic wounds, and the positive data observed in the CLEANVLU Phase IIa trial brings us another step closer.”

Further validating SolasCure’s innovative approach to wound care, the Company was recently selected for the EIC Accelerator Horizon grant which recognises the potential impact the innovative technology could have on the lives of patients suffering from chronic wounds without adequate solutions.

For more information about SolasCure, please visit: https://solascure.com/.

  1. Olsson, M. et al. (2018) ‘The humanistic and economic burden of chronic wounds: A systematic review’, Wound Repair and Regeneration, 27(1), pp. 114–125. doi:10.1111/wrr.12683

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    SolasCure. (2023, December 12). SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel. News-Medical. Retrieved on October 09, 2024 from https://www.news-medical.net/news/20231212/SolasCure-demonstrates-proof-of-concept-in-Phase-lla-safety-trial-of-Aurase-Wound-Gel.aspx.

  • MLA

    SolasCure. "SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel". News-Medical. 09 October 2024. <https://www.news-medical.net/news/20231212/SolasCure-demonstrates-proof-of-concept-in-Phase-lla-safety-trial-of-Aurase-Wound-Gel.aspx>.

  • Chicago

    SolasCure. "SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel". News-Medical. https://www.news-medical.net/news/20231212/SolasCure-demonstrates-proof-of-concept-in-Phase-lla-safety-trial-of-Aurase-Wound-Gel.aspx. (accessed October 09, 2024).

  • Harvard

    SolasCure. 2023. SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel. News-Medical, viewed 09 October 2024, https://www.news-medical.net/news/20231212/SolasCure-demonstrates-proof-of-concept-in-Phase-lla-safety-trial-of-Aurase-Wound-Gel.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SolasCure publishes phase IIa clinical trial report in leading wound care journal